特定于Codon的KRAS突变预测了晚期胰腺癌的存活率
A Boilève1,2,3, A Rousseau3,4,5, M Hilmi6
1INSERM U1279, Gustave Roussy, Villejuif.
ESMO gastrointestinal oncology
|February 6, 2026
概括
在胰腺癌中患有KRAS G12突变的患者的预后比患有其他KRAS突变的患者更差. 这突显了特定的KRAS变化的重要性在胰腺管腺癌 (PDAC) 结果.
科学领域:
- 在瘤学瘤学.
- 遗传学 是一个遗传学.
- 分子生物学分子生物学
背景情况:
- 显著的KRAS改变对胰腺腺癌 (PDAC) 发病和结果的影响尚不清楚.
- 新的KRAS G12抑制剂正在出现,但患者亚组的结果需要进一步描述.
- 这项研究调查了PDAC中子特异性KRAS突变 (G12与其他) 之间的差异.
研究的目的:
- 基于codon特定的KRAS突变,比较PDAC患者的临床和基因组特征.
- 分析不同KRAS突变组的基因表达特征和体外药物敏感性.
- 评估KRAS G12与PDAC中的其他KRAS突变的预后意义.
主要方法:
- 具有可用的分子概况的转移性PDAC患者的回顾性分析 (2015-2022年).
- 包括具有KRAS突变的患者;分析了69个瘤的转录组数据.
- 在 KRAS G12 和 KRAS 其他组之间比较临床病理特征,可采取行动的变化,存活率和治疗反应.
主要成果:
- 包括263名患者:239名KRAS G12 (91%) 和24名其他KRAS (9%).
- 临床病理学特征或可采取行动的变化没有显著差异,除了其他KRAS中的BRAF (p=0.01) 和GNAS (p=0.002).
- 其他KRAS (24.9个月) 与KRAS G12 (16.7个月) (HR=0.56,p=0.04调整) 的中位整体存活时间明显较长;在KRAS G12瘤中,免疫路径被调高.
结论:
- 在PDAC中,codon特定的KRAS突变具有不平等的预后影响.
- 与其他KRAS患者相比,KRAS G12患者的预后更差.
- 需要进一步的大规模研究来证实这些发现.
更多相关视频
09:18Multianimal Magnetic Resonance Imaging for Tumor Measurements in Pancreatic Cancer Mouse Models
Published on: February 3, 2026
26
13:34A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
10.6K
相关概念视频
Mutations
94.5K
Overview
94.5K
Mutations
44.6K
Mutations are changes in the sequence of DNA. These changes can occur spontaneously or they can be induced by exposure to environmental factors. Mutations can be characterized in a number of different ways: whether and how they alter the amino acid sequence of the protein, whether they occur over a small or large area of DNA, and whether they occur in somatic cells or germline cells.
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
44.6K
Sensitivity, Specificity, and Predicted Value
1.4K
In healthcare diagnostics, laboratory tests play a crucial role in identifying and diagnosing a wide range of medical conditions. However, interpreting test results is not always straightforward. An abnormal test result does not always confirm the presence of a disease, just as a normal result does not guarantee its absence. To assess the reliability of these diagnostic tools, healthcare practitioners rely on two key statistical indicators: sensitivity and specificity.
Sensitivity is the...
Sensitivity is the...
1.4K
Cancer Survival Analysis
769
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
769
Cancers Originate from Somatic Mutations in a Single Cell
14.9K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
14.9K
Viral Mutations
39.9K
A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material...
39.9K
